Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).
2025 · 2nd Quarter (Apr 1 - June 30)
EXELIXIS, INC.
Filed by ARNOLD & PORTER KAYE SCHOLER LLP.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 17, 2025
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- ARNOLD & PORTER KAYE SCHOLER LLP
- Client
- EXELIXIS, INC.
- Filing UUID
- 3b90da66-0851-4af4-ac0e-7b32224892de
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program. Issues related to biopharmaceutical intellectual property and patent matters.
Issues related to research and development (R&D) tax credits.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.